Cargando…

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Parth, Rani, Ruma, Solanki, Raghu, Patel, Vishal Haribhai, Mukherjee, Tapan Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645466/
https://www.ncbi.nlm.nih.gov/pubmed/37970206
http://dx.doi.org/10.37349/etat.2023.00171
_version_ 1785147376943497216
author Malik, Parth
Rani, Ruma
Solanki, Raghu
Patel, Vishal Haribhai
Mukherjee, Tapan Kumar
author_facet Malik, Parth
Rani, Ruma
Solanki, Raghu
Patel, Vishal Haribhai
Mukherjee, Tapan Kumar
author_sort Malik, Parth
collection PubMed
description Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more than 80% of which are explicitly caused by tobacco smoking. Prevailing as small and non-small cell pathologies, with respective occurring frequency of nearly 15% and 80–85%, non-small cell LCs (NSCLCs) are prominently distinguished into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), subtypes. Since the first use of epidermal growth factor receptor (EGFR) inhibitor gefitinib for NSCLC treatment in 2002, immense progress has been made for targeted therapies with the next generation of drugs spanning across the chronological generations of small molecule inhibitors. The last two years have overseen the clinical approval of more than 10 therapeutic agents as first-line NSCLC medications. However, uncertain mutational aberrations as well as systemic resistant responses, and abysmal overall survival curtail the combating efficacies. Of late, immune checkpoint inhibitors (ICIs) against various molecules including programmed cell death-1 (PD-1) and its ligand (PD-L1) have been demonstrated as reliable LC treatment targets. Keeping these aspects in mind, this review article discusses the success of NSCLC chemo and immunotherapies with their characteristic effectiveness and future perspectives.
format Online
Article
Text
id pubmed-10645466
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Open Exploration Publishing
record_format MEDLINE/PubMed
spelling pubmed-106454662023-11-15 Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies Malik, Parth Rani, Ruma Solanki, Raghu Patel, Vishal Haribhai Mukherjee, Tapan Kumar Explor Target Antitumor Ther Review Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more than 80% of which are explicitly caused by tobacco smoking. Prevailing as small and non-small cell pathologies, with respective occurring frequency of nearly 15% and 80–85%, non-small cell LCs (NSCLCs) are prominently distinguished into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), subtypes. Since the first use of epidermal growth factor receptor (EGFR) inhibitor gefitinib for NSCLC treatment in 2002, immense progress has been made for targeted therapies with the next generation of drugs spanning across the chronological generations of small molecule inhibitors. The last two years have overseen the clinical approval of more than 10 therapeutic agents as first-line NSCLC medications. However, uncertain mutational aberrations as well as systemic resistant responses, and abysmal overall survival curtail the combating efficacies. Of late, immune checkpoint inhibitors (ICIs) against various molecules including programmed cell death-1 (PD-1) and its ligand (PD-L1) have been demonstrated as reliable LC treatment targets. Keeping these aspects in mind, this review article discusses the success of NSCLC chemo and immunotherapies with their characteristic effectiveness and future perspectives. Open Exploration Publishing 2023 2023-10-10 /pmc/articles/PMC10645466/ /pubmed/37970206 http://dx.doi.org/10.37349/etat.2023.00171 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Malik, Parth
Rani, Ruma
Solanki, Raghu
Patel, Vishal Haribhai
Mukherjee, Tapan Kumar
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title_full Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title_fullStr Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title_full_unstemmed Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title_short Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
title_sort understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645466/
https://www.ncbi.nlm.nih.gov/pubmed/37970206
http://dx.doi.org/10.37349/etat.2023.00171
work_keys_str_mv AT malikparth understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies
AT raniruma understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies
AT solankiraghu understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies
AT patelvishalharibhai understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies
AT mukherjeetapankumar understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies